Message
  • EU e-Privacy Directive

    This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

    View e-Privacy Directive Documents

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metas

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.

 

Abstract

BACKGROUND:

Acidity is a hallmark of malignant tumor, representing a very efficient mechanism of chemoresistance. Proton pump inhibitors (PPI) at high dosage have been shown to sensitize chemoresistant human tumor cells and tumors to cytotoxic molecules. The aim of this pilot study was to investigate the efficacy of PPI in improving the clinical outcome of docetaxel?+?cisplatin regimen in patients with metastatic breast cancer (MBC).

METHODS:

Patients enrolled were randomly assigned to three arms: Arm A, docetaxel 75 mg/m(2) followed by cisplatin 75 mg/m(2) on d4, repeated every 21 days with a maximum of 6 cycles; Arm B, the same chemotherapy preceded by three days esomeprazole (ESOM) 80 mg p.o. bid, beginning on d1 repeated weekly. Weekly intermittent administration of ESOM (3 days on 4 days off) was maintained up to maximum 66 weeks; Arm C, the same as Arm B with the only difference being dose of ESOM at 100 mg p.o. bid. The primary endpoint was response rate.

RESULTS:

Ninety-four patients were randomly assigned and underwent at least one injection of chemotherapy. Response rates for arm A, B and C were 46.9, 71.0, and 64.5 %, respectively. Median TTP for arm A (n?=?32), B (n?=?31), C (n?=?31) were 8.7, 9.4, and 9.7 months, respectively. A significant difference was observed between patients who had taken PPI and who not with ORR (67.7 % vs. 46.9 %, p?=?0.049) and median TTP (9.7 months vs. 8.7 months, p?=?0.045) [corrected]. Exploratory analysis showed that among 15 patients with triple negative breast cancer (TNBC), this difference was bigger with median TTP of 10.7 and 5.8 months, respectively (p?=?0.011). PPI combination showed a marked effect on OS as well, while with a borderline significance (29.9 vs. 19.2 months, p?=?0.090). No additional toxicity was observed with PPI.

CONCLUSIONS:

The results of this pilot clinical trial showed that intermittent high dose PPI enhance the antitumor effects of chemotherapy in MBC patients without evidence of additional toxicity, which requires urgent validation in a multicenter, randomized, phase III trial.

 

https://www.ncbi.nlm.nih.gov/pubmed/26297142

 

 

Hear this article
Attachments:
Download this file (yun wang jeccr 2015.pdf)yun wang jeccr 2015.pdf[Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer]1063 Kb
 
Language Selection
English (United Kingdom)Italian - ItalyDeutsch (DE-CH-AT)Español(Spanish Formal International)French (Fr)
Prossimi Eventi
Cena con Erbe Spontanee D'Estate

IL CASALE DEI BUONI SAPORI

in collaborazione con

CASA DELLE ERBE DELLA TUSCIA E DEL MONTE SORATTE

 

 

Mercoledì 28 Giugno 2017

ore 20.00

 

IL CASALE DEI BUONI SAPORI

Statale Nepesina 311, Loc. Colonnetta - NEPI

 

Info e Prenotazioni Alessandro Sgamuffa

0761 571504  -  338 1385912

 

 

Read more...
Support Cybermed

 

Cybermed ADV
Follow us on

Visitors Counter
mod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_countermod_vvisit_counter
mod_vvisit_counterToday10925
mod_vvisit_counterYesterday40019
mod_vvisit_counterThis week50944
mod_vvisit_counterLast week248796
mod_vvisit_counterThis month1269692
mod_vvisit_counterLast month2406870
mod_vvisit_counterAll days99195597

We have: 816 guests, 16 bots online
Your IP: 54.198.201.250
 , 
Today: Jun 27, 2017